Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Rasburicase in Advanced B-Cell Leukemia/Lymphoma
NCT00057811Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2004
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoblastic leukemia (B-ALL), sponsored by Children's Oncology Group. Primary endpoints: Grade ≥ 3 Stomatitis at 1 year, Response Rate at 5 years and 1 more. Started Jun 2004; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT00057811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057811.